Bill & Melinda Gates FoundationGlobal Grand Challenges
  • Grant Opportunities
  • Challenges
  • Awards
  • Champions
  • Partnerships
  • News
  • About

Ribonuclease Zymogen as an HIV Chemotherapeutic

Ron Raines of the University of Wisconsin proposes to convert a ribonuclease that rapidly degrades RNA into a zymogen, an enzyme precursor that is activated only when cleaved by an HIV protease. Because this cleaving can only occur within HIV-infected cells, the toxic activity of the ribonuclease will be unleashed only in cells in which HIV is active.

More information about Create Drugs and Delivery Systems to Limit Drug Resistance (Round 1)